Baker Avenue Asset Management’s Solid Biosciences SLDB Stock Holding History

Baker Avenue Asset Management’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-66	Closed	-$346	–	1720
2023 Q2	$346	Hold	66	–	–	﹤0.01%	1513
2023 Q1	$313	Buy	+66	New	+$397	﹤0.01%	1561

Other funds holding SLDB

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Alyeska Investment Group

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baker Avenue Asset Management's SLDB Position: Q3 2023 in Review

Baker Avenue Asset Management sold out of Solid Biosciences (SLDB) in Q3 2023, closing a stake of 66 shares — an estimated $346 sold.

Baker Avenue Asset Management first reported a position in SLDB in Q1 2023 and held it in 2 quarters. The position peaked at $346 in Q2 2023. 36 funds tracked by Wall St. Rank hold SLDB as of Q3 2023.

Baker Avenue Asset Management reported no remaining Solid Biosciences position as of Q3 2023 after selling out during the quarter.
Baker Avenue Asset Management sold 66 Solid Biosciences shares in Q3 2023, an estimated $346.
Baker Avenue Asset Management first reported a position in Solid Biosciences in Q1 2023 and held it in 2 quarters.
Baker Avenue Asset Management's Solid Biosciences position peaked at $346 in Q2 2023.
36 funds tracked by Wall St. Rank held Solid Biosciences as of Q3 2023.

Based on Baker Avenue Asset Management's 13F filing for Q3 2023, filed 15 Nov 2023.